AnaptysBio.jpg
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
May 04, 2021 16:05 ET | AnaptysBio, Inc.
Imsidolimab Phase 3 GPP trial anticipated to commence in mid-2021 following FDA end-of-Phase 2 meeting held during Q2 2021JEMPERLI (dostarlimab), our PD-1 antagonist antibody partnered with...
AnaptysBio.jpg
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe
April 23, 2021 10:31 ET | AnaptysBio, Inc.
PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to...
AnaptysBio.jpg
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
April 22, 2021 16:12 ET | AnaptysBio, Inc.
PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to...
AnaptysBio.jpg
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
April 12, 2021 16:00 ET | AnaptysBio, Inc.
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio.jpg
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint
March 08, 2021 08:00 ET | AnaptysBio, Inc.
Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpointImsidolimab was generally well tolerated and no...
AnaptysBio.jpg
AnaptysBio Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Pipeline Updates
February 25, 2021 16:05 ET | AnaptysBio, Inc.
Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020, with Phase 3 trial initiation anticipated...
AnaptysBio.jpg
AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021 16:15 ET | AnaptysBio, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio.jpg
AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference
November 13, 2020 09:25 ET | AnaptysBio, Inc.
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio.jpg
AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates
November 04, 2020 16:00 ET | AnaptysBio, Inc.
Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe Generalized Pustular Psoriasis (GPP) announced in October 2020 FDA end-of-Phase 2 meeting anticipated in...
AnaptysBio.jpg
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
October 26, 2020 08:00 ET | AnaptysBio, Inc.
Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020Additional 1% royalty to AnaptysBio on GSK’s...